A high genetic barrier to resistance to the integrase strand transfer inhibitor (INSTI) dolutegravir has been reported in vitro and in vivo. We describe the dynamics of INSTI resistance-associated mutations (INSTI-RAMs) and mutations in the 3ʹ-polypurine tract (3ʹ-PPT) in relation to virologic failure (VF) observed in the randomized Dolutegravir as Maintenance Monotherapy for HIV-1 study (DOMONO, NCT02401828).
The second-generation integrase strand-transfer inhibitor (INSTI) dolutegravir (DTG) seems to have a high genetic barrier to resistance in vitro, with significant loss of replication capacity in viruses with INSTI resistance-associated mutations (RAMs), compared with wild-type viruses [1, 2] . The high genetic barrier to DTG resistance when administered as DTG-containing combination antiretroviral therapy (cART) is already demonstrated in vivo: no RAMs associated with decreased DTG susceptibility were observed in 1067 treatment-naive patients who initiated DTG-containing cART in pivotal phase 3 studies [3] [4] [5] . In treatment-experienced but INSTI-naive patients taking a DTG-containing cART regimen, virologic failure (VF) with development of INSTI-RAMs is rare [6, 7] . Furthermore, mutations selected by the first-generation INSTIs raltegravir (RAL) and elvitegravir (EVG) might have limited impact on DTG susceptibility, enabling successful treatment with DTG-containing cART in a large proportion of patients who previously did not respond to cART containing RAL or EVG, although use of DTG twice daily is necessary [7] [8] [9] [10] [11] .
Given the high genetic barrier to DTG resistance and other favorable properties of DTG therapy, such as few drug-drug interactions, few adverse events, and a low pill burden, we hypothesized that DTG could be used as monotherapy to maintain viral suppression in human immunodeficiency virus type 1 (HIV-1)-infected adults with long-term virologic suppression during cART. More recently, DTG maintenance monotherapy has been investigated in small, retrospective, observational studies and case series, which showed high rates of virologic suppression without emergence of INSTI-RAMs in INSTI-naive patients. These studies included 118 patients; VF in 5 led to development of INSTI-RAMs, but all 5 were INSTI experienced or had treatment-compliance issues. Also, these studies were done in routine clinical care and without standardized monitoring and ethics committee approval [12] [13] [14] [15] [16] . As these results lacked a control arm, we conducted the randomized, controlled Dolutegravir as Maintenance Monotherapy for HIV-1 study (DOMONO, clinical trials registration NCT02401828) and showed that DTG maintenance monotherapy in HIV-1-infected patients led to a higher rate of VF (in 8 of 95 patients [8%]), compared with patients who continued cART (3 of 152 [2%]) [17] .
Since INSTI-RAMs in the integrase gene are rarely detected in patients with virologic failure to DTG-containing cART [5, 6] , novel DTG resistance pathways outside of the integrase gene may exist. Experiments with purified integrase enzyme and long terminal repeat (LTR) duplexes showed that mutations in the 4 terminal bases of the LTR could confer INSTI resistance [18] . Furthermore, in vitro DTG resistance selection experiments showed that mutations in the 3ʹ-polypurine tract (3ʹ-PPT) confer high-level resistance to RAL, EVG, and DTG [19] . Both resistance pathways have not been reported yet in HIV-1-infected individuals. Here, we describe the dynamics of resistance-associated mutations in the integrase gene and the 3ʹ-PPT in HIV-1-infected individuals with VF during DTG maintenance monotherapy.
METHODS AND MATERIALS

Study Population
Patients with VF during DTG maintenance monotherapy were included from 2 studies performed in the outpatient clinic of the Erasmus University Medical Center (Rotterdam, the Netherlands) and University Medical Center Groningen (Groningen, the Netherlands). The first group of patients consisted of participants in the DOMONO main study. The most important inclusion criteria were a nadir CD4 + T-lymphocyte count of >200 cells/mm 3 , a peak HIV-1 RNA load of <100 000 copies/mL (except when measured during the acute phase of infection), and no previous VF and/ or any documented RAMs, according to the Stanford HIV Drug Resistance Database [20] . The second group of patients consisted of participants in the DOMONO pilot study. This pilot study had the same inclusion and exclusion criteria as the main study, with the exception that patients with a nadir CD4 + T-lymphocyte count of <200 cells/mm 3 were included.
Study Procedures
HIV-1 RNA in plasma was quantified with the Cobas AmpliPrep/ COBAS TaqMan HIV-1 test, version 2 (Roche Diagnostics, Almere, the Netherlands). VF was defined as a confirmed plasma HIV-1 RNA level of >200 copies/mL. Adherence was defined as the percentage of participants self-reporting adherence. DTG plasma concentrations at the moment of VF were determined and interpreted according to the therapeutic drug monitoring protocol of Radboud University Medical Center (Nijmegen, the Netherlands) [21] .
In all patients, Sanger sequences covering the integrase gene and the 3′-PPT and the four 5′ terminal bases of the 3′-LTR in the nef gene were determined using stored plasma samples with detectable HIV-1 RNA before patients started cART (baseline samples) and in plasma samples at time of VF during treatment with DTG monotherapy. For nef amplification, RNA was isolated with the High Pure Viral RNA kit (catalog no. 11858882001; Roche) according to the manufacturer's instructions. Of 60 µL of eluted RNA, 12.5 µL was used for complementary DNA synthesis, using 50 pmol oligo dT primer (20T+TRAAG, Eurogentec) and Superscript IV (ThermoFisher), with the following polymerase chain reaction (PCR) conditions: 5 minutes at 30°C, 2 hours at 50°C, and 10 minutes at 80°C.
After RNase H inactivation (by incubation for 20 minutes at 37°C and 15 minutes at 70°C), 5 µL of complementary DNA was used for PCR analysis. Primers were as follows: HXB2-8343 (forward; T [or C]): AGAGTTAGGCAGGGATAT(C)TCACC; and HXB2-9632 (reverse), GCACTCAAGGCAAGCTTTATTGAGGCT. PCR conditions were as follows: 2 minutes at 94°C and 40 cycles of 10 seconds at 94°C, 30 seconds at 60°C, and 1 minute at 68°C, and 10 minutes at 68°C (extension). PCR samples were separated on 1% agarose, and bands were cut and extracted with Qiaex II gel extraction kit (Qiagen) before sequencing.
For integrase sequencing, nucleic acids were extracted using MPLC (Roche) after ultracentrifugation of 1.5 mL of ethylenediaminetetraacetic acid-plasma at 26.000×g for 1 hour at 4°C. Subsequently, the HIV-1 integrase gene was amplified with the OneStep reverse-transcription PCR kit (Qiagen, Venlo, the Netherlands) and 20 pmol of primers described in Supplementary Table 1, according to the manufacturer's protocol, using the following thermal profile: 30 minutes at 50°C, 15 minutes at 95°C, and 25 cycles of 1 minute at 95°C, 1 minute at 55°C, 2 minutes at 72°C, and 10 minutes at 72°C. Nested PCR was then performed with the HotStar HiFidelity Polymerase kit according to the manufacturer's protocol and the following thermal profile: 5 minutes at 95°C and 30 cycles of 15 seconds at 94°C, 1 minute at 50°C, 2 minutes at 72°C, and 10 minutes at 72°C. One microliter of the amplicon was sequenced using the BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Nieuwerkerk a/d IJssel, the Netherlands) and 5 pmol of sequencing primers described in Supplementary Table 1 . The sequenced PCR products were purified using the Performa DTR V3 purification plate (Edgebio, Sopachem, Ochten, the Netherlands) and analyzed on an ABI 3130XL sequencer (Applied Biosystems). The sequence data were analyzed using a Sequence Navigator software sequencer (Applied Biosystems) and SeqMan, version 10.1.2 (DNAStar, Madison, WI). Resulting HIV-1 integrase sequences were further analyzed using the Stanford database to check for known drug resistanceassociated mutations, and baseline sequences were compared to rebound sequences by using BioEdit, version 7.2.0 [20] .
Ethical Considerations
The DOMONO main study and its pilot study were approved by the Dutch Medical Ethics Committee and were performed in accordance with good clinical practice and the Helsinki Declaration. All participating subjects provided verbal and written informed consent before study procedures.
RESULTS
Patient Population and Baseline Characteristics.
Eight of 95 participants in the DOMONO main study had VF. Of the 4 participants in the DOMONO pilot study, 2 had VF. In total, 10 patients experienced VF during DTG maintenance monotherapy. Baseline characteristics at entry into the DTG maintenance monotherapy study are listed in Table 1 . All participants were male and infected with HIV-1 subtype B, and the median age was 46 years. The median peak HIV-1 RNA load was 29 750 copies/mL, and the median nadir CD4 + T-lymphocyte count was 235 cells/mm 3 . In 3 patients (patients 5, 9, and 10), cART was initiated within a year after they received a diagnosis of HIV-1 infection. Nine participants with VF were INSTI naive, whereas 1 patient (patient 3) was previously treated successfully with RAL-containing cART and DTG-containing cART. The median duration of plasma HIV-1 RNA suppression (defined as an HIV-1 RNA load of <50 copies/mL) during cART (ie, before initiation of DTG maintenance monotherapy) was 61 months.
Characteristics of VF During DTG Maintenance Monotherapy
Clinical and virologic characteristics at the moment of VF are shown in Tables 2 and 3 . Median HIV-1 RNA load at VF was 3490 copies/mL (IQR, 1440-4990 copies/mL). Interestingly, the time to VF after the start of DTG maintenance monotherapy varied considerably, with patient 4 already experiencing VF at week 4 and patient 7 experiencing VF at week 72. The median time to VF was 33 weeks. Self-reported adherence was >95%, and DTG plasma concentrations during DTG maintenance monotherapy were adequate (ie, >0.50 mg/L) in all patients at time of VF. Two patients received comedications (patient 3 received oxazepam, buprenorphine/naloxone, fluticasone, quetiapine, levomepromazine, and prednisolone; patient 5 received simvastatin, acetylsalicylic acid, tolbutamid, perindopril, and metoprolol), but no drug-drug interactions were detected. No INSTI-RAMs were detected in samples obtained from patients before they started therapy. At the moment of VF detection, INSTI-RAMs were detected in patients 2, 5, 7, and 9, whereas no known INSTI-RAMs were detected in patients 1, 4, 8, and 10; integrase gene sequencing was unsuccessful in patients 3 and 6, owing to low plasma HIV-1 RNA levels of 1440 and 678 copies/ mL. Single INSTI-RAMs were detected in 3 patients: S230R (in patient 2), R263K (in patient 5), and N155H (in patient 7). In patient 9, the combination of E92Q and N155H was detected. Figure 1 shows plasma HIV-1 RNA levels and INSTI-RAMs detected in patients during DTG maintenance monotherapy.
To investigate the role of an alternative resistance mechanism, we sequenced the nef gene, including the 3′-PPT and four 5′ terminal bases of the 3′-LTR, because mutations in these sites can confer resistance to INSTIs [18, 19] . No mutations were observed in the four 5′ terminal bases of the 3′-LTR at baseline or at VF in any patients. In 9 of 10 patients, we did not detect changes in the 3′-PPT located in the nef gene. However, in patient 10, who did not develop INSTI-RAMs in the integrase gene, the wild-type G stretch of the 3′-PPT was observed at baseline (ie, GGGGGG), but at VF 2 changes were detected (ie, GGGAGC; Figure 2 ).
Virologic Response After Restart of cART
At the moment of confirmed VF, DTG maintenance monotherapy was stopped, and all patients restarted their previous cART regimen. The patients responded well to cART restart, including the patient who restarted treatment with dolutegravir, emtricitabine, and tenofovir. In all patients, plasma HIV-1 RNA levels declined to <20 copies/mL and remained at <20 copies/mL for a mean of 39.7 weeks of follow-up.
DISCUSSION
In the main DOMONO study, we recently showed that a higher proportion of patients treated with DTG maintenance monotherapy experienced VF, compared with patients who continued to receive cART [17] . In addition, 50% of participants (2 of 4) in the DOMONO pilot study, in which patients had a nadir CD4 + T-cell count of <200 cells/mm 3 , had VF. The same observation was previously made during maintenance monotherapy with protease inhibitors [22] . Moreover, of the 10 patients with VF in the main study and pilot study combined, we observed the emergence of INSTI-RAMs in 4 INSTI-naive patients: N155H (in patient 7), E92Q+N155H (in patient 9), R263K (in patient 5), and S230R (in patient 2). These results The timing of sample collection after intake of the last DTG dose is specified in parentheses. [23] . Emergence of the R263K mutation has previously been observed in the SAILING study in treatment-experienced, INSTI-naive patients who did not respond to DTG-containing cART [6, 24] , and in the VIKING study the N155H mutation emerged in patients with HIV-1 resistant to RAL and/or EVG who were treated with DTG-containing cART [11, 25] .
Furthermore, emergence of N155H and E92Q+N155H was noted in the retrospective, observational Redomo study in patients with VF during DTG maintenance monotherapy [23] .
To our best knowledge, the S230R mutation has been described previously in 1 patient in whom DTG-containing cART was failing [26] . Interestingly, development of the S230R mutation was observed in 1 of 5 HIV-1-infected humanized mice treated with DTG monotherapy. However, in that study the S230R mutation was detected in combination with E138K, G140S, Q148H, and N155H [27] . In vitro, the N155H, N155H+E92Q, and R263K mutations caused 1-2-, 2.5-, and 2-4-fold changes, respectively, in the half-maximal inhibitory concentration (IC 50 ) of DTG and conferred only low-level resistance to DTG [9, 28, 29] . In the companion article in this issue of the Journal, Pham et al characterized the S230R substitution and showed that it resulted in a 4-fold change in IC 50 of DTG in tissue culture resulting in low level resistance to DTG [30] . When combining these results with our observations in vivo, it appears that single INSTI-RAMs that result in a relatively small fold increase in the IC 50 of DTG are sufficient to cause VF in patients receiving DTG maintenance monotherapy. In our study, plasma HIV-1 RNA levels were relatively low (ie, <1000 copies/mL) in 8 of 10 patients who experienced VF, compared with peak levels before cART initiation. This suggests that DTG still exhibited partial antiretroviral activity. It should be noted that our patients received DTG 50 mg once daily and that treatment with higher doses of DTG may be sufficient to overcome this partial resistance and fully suppress replication of these viruses [11] .
In 4 patients with VF (ie, patients 1, 4, 8, and 10), no known INSTI-RAMs were detected. For these patients, we compared the pre-cART integrase sequence with the integrase sequence during VF and found amino acid changes at the following positions: E10, E11, S17, S24, V32, L45, M50, I72, L101, K111, T112, T124, I135, K211, I220, D229, and S283. Mutations at these positions occur at frequencies of >1% in INSTI-naive patients [31] . These mutations have not been shown to increase the IC 50 of DTG in vitro [31] [32] [33] , although we cannot exclude that certain combinations of these mutations result in a decreased susceptibility to DTG. VF could also be explained by therapy nonadherence, but this seems unlikely because only therapy-adherent patients with no history of VF were included in our study and because DTG plasma concentrations were adequate at the time of VF.
To find an explanation for VF, we searched for mutations outside of the integrase gene that may confer INSTI resistance in all 10 patients. Therefore, we sequenced the 5′ terminal bases of the U3 region of the LTR (ie, ACTG), which are the substrate for integrase in the integration process [18] . Dicker et al showed with purified integrase enzymes and LTR duplexes that certain mutations in the 4 terminal bases of the LTR led to decreased binding of INSTI to integrase, while the strand-transfer activity of integrase remained relatively intact [18] . These mutations have not been reported in HIV-1 culture experiments or in vivo.
In this study, we did not detect changes in the ACTG motif of the 3′-LTR in patients with VF. Simultaneously, we sequenced the 3′-PPT region adjacent to the 3′-LTR, because mutations in this region have been linked to INSTI resistance [19] . Malet et al recently showed in in vitro HIV-1 culture experiments involving high doses of DTG that mutations located in the nef gene led to INSTI resistance [19] . The A→C mutation located 6 nucleotides upstream of the 3′-PPT motif, in combination with 4 changes in the G-stretch of the 3′-PPT motif (GGGGGG → GCAGTdel), conferred high-level resistance to DTG, RAL, and EVG. In our study, we detected mutations in the G-stretch of the 3′-PPT in virus from patient 10 that were not present at baseline (GGGGGG → GGGAGC). Interestingly, a high DTG plasma concentration was detected during VF in this patient, and the mutations in 3′-PPT described by Malet et al were also selected using high DTG concentrations in vitro. In addition, no known INSTI-RAMs in the integrase gene were detected in this patient.
The 3′-PPT sequence is >99.9% conserved among HIV-1 sequences in the Los Alamos database, as it serves as hybridization site for the RNA primer for plus-strand DNA synthesis during reverse transcription. Removal of these RNA primers is pivotal because it defines the end of the linear proviral DNA for integration [34] . The GGGGGG → GGGAGC mutations in the 3′-PPT observed in patient 10 result in a glycine to alanine change in the Nef protein, and the mutations in the 3′-PPT described by Malet et al result in a truncated Nef protein. It seems unlikely, however, that Nef protein plays a role in INSTI resistance, since there is hardly data that the Nef protein plays any role in the proviral integration process and because a previous study reported full susceptibility to RAL of Nefdeficient HIV-1 [35] .
The terminal 200-250 base pairs of each proviral DNA end are the primary protein binding sites of the HIV-1 intasome [36, 37] . Since the 3′-PPT in the unintegrated linear proviral DNA intermediate is located approximately 9000 base pairs from the 5′-LTR and approximately 800 base pairs from the end of the 3′-LTR, it is unlikely that the 3′-PPT interacts with the HIV-1 intasome.
Notwithstanding the findings described above, the 3′-PPT plays a major role in defining the proviral DNA end of the 5′-LTR. Previous studies on the reverse transcription process showed that mutations in the G stretch of the 3′-PPT can lead to incomplete removal of the 3′-PPT RNA primer by RNAse H or to an alternative starting point for plus-strand DNA synthesis [34, [38] [39] [40] . Both scenarios would lead to an altered end of the unintegrated linear proviral DNA intermediate at the 5′-LTR site. In addition, production of viral particles from unintegrated proviral DNA has been proposed. In patient 10, we observed the emergence of different mutations in the 3′-PPT, compared with the virus described by Malet et al. This indicates that other mutations in 3′-PPT may also cause INSTI resistance. However, experiments with site-directed mutants are needed to prove that the GGGGGG → GGGAGC mutations in 3′-PPT indeed cause INSTI resistance. In addition, further studies are needed to unravel the mechanism of INSTI resistance caused by mutations in 3′-PPT.
Still, for 3 patients we could not find a cause of VF. Of note is patient 4, who had adequate plasma DTG levels and experience VF 4 weeks after starting DTG maintenance monotherapy, with a plasma HIV-1 RNA level of 71 600 copies/mL. Ultra-deep sequencing of plasma HIV-1 RNA or proviral DNA in peripheral blood mononuclear cells during VF might show minority variants that harbor resistance-associated mutations in integrase or 3′-PPT, which could partially explain VF. Unfortunately, samples needed for these analyses were not available. VF in these patients might also be explained by yet another novel resistance pathway, which would require whole-virus genome sequencing at baseline and during VF and phenotyping of the emerged mutations with site-directed mutants. In addition, VF in these patients could be explained by replication of HIV-1 in sanctuary sites in which DTG does not penetrate, with subsequent spillover of HIV-1 to peripheral blood.
The origin of the viruses detected during VF in this study is currently unknown. These viruses might originate from ongoing low-level replication in sanctuary sites during cART that are not detectable in plasma. However, Joos et al showed that after patients with long-term virologic suppression (defined as a plasma HIV-1 RNA load of <50 copies/mL) stopping cART, the rebound viruses detected in plasma originate from reactivation of latently infected cells instead of viral lineages that continuously replicate at low levels [41] . Reactivation of HIV-1 from latently infected cells is a stochastic process that occurs on average every 5-8 days and depends on the size of the replication-competent viral reservoir. This may also explain why 2 of 4 patients who had a nadir CD4 + T-cell count of <200 cells/mm 3 and were included in the DOMONO pilot study went on to have VF. Indeed, a low nadir CD4 + T-cell count is correlated with a larger viral reservoir [42, 43] . Owing to the error-prone nature of HIV-1 replication, minority populations with drug-resistant mutants harboring single resistance mutations are most likely generated before therapy is initiated and persist in the proviral archive [44, 45] . We hypothesize that the viruses detected during VF in this study originate from stochastic reactivation of a single cell harboring a provirus with a preexisting INSTI-RAM. Reactivation of wild-type virus from latently infected cells will not result in further rounds of replication, because these viruses are inhibited by DTG. However, reactivation of a virus carrying a single INSTI-RAM is not fully inhibited by DTG, and further rounds of replication will lead to detectable HIV-1 RNA levels in plasma. This hypothesis is supported by the large variation observed in the timing of VF, owing to the stochastic nature of reactivation of proviruses carrying a single INSTI-RAM.
In conclusion, the genetic barrier to DTG resistance is too low to justify DTG maintenance monotherapy, even in treatment-adherent patients with a relatively low peak HIV-1 RNA load and high nadir CD4 + T-lymphocyte count. The exact mechanism of VF in HIV-1 infected individuals with long-term virologic suppression who switch to DTG maintenance monotherapy is currently unclear, but we propose stochastic reactivation of a single cell harboring a provirus with a preexisting INSTI-RAM as mechanism for VF. Mutations in the G stretch of the 3′-PPT region might confer an alternative DTG resistance pathway.
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